Merck Acquires Rapid Micro Biosystems for Pharma QC Automation
Proposed acquisition would strengthen the company’s quality-control workflow offering with Rapid Micro Biosystems’ Growth Direct automated microbial quality-control platform.

Merck has agreed to acquire Rapid Micro Biosystems, a maker of instruments, consumables, software, and services that automate microbial quality-control testing in pharmaceutical manufacturing. The deal would combine Rapid Micro's Growth Direct platform with Merck's quality-control portfolio. Merck would pay US$0.75 per share in cash.
“Quality control is essential to the reliable manufacture of medicines,” said Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck. “Our customers need reliable results faster, more efficient quality-control workflows and robust data integrity to support regulatory compliance. Rapid Micro Biosystems will strengthen our ability to meet those needs, building on our existing offering and bringing greater automation to a critical step in pharmaceutical manufacturing.”
Rapid Micro Biosystems' Growth Direct platform automates microbial quality control testing, from sample incubation to imaging and colony counting. Pharmaceutical manufacturers use it for environmental monitoring, water and bioburden testing. By detecting microbial growth during incubation, it delivers results faster than manual methods and lets quality teams act sooner. It also digitizes sample tracking and results, cutting manual transcription and protecting data integrity. As biologics and cell and gene therapies grow more complex, that speed and connected data matter more than ever.
The proposed acquisition would build on the portfolio of pharmaceutical quality-control products and workflow solutions in Merck’s Life Science business sector, spanning environmental monitoring, in-process testing and release testing. Rapid Micro Biosystems’ automated microbial detection and data-management capabilities would strengthen this offering, supporting Merck’s increased focus on integrated workflow solutions as part of its mid- to long-term strategic agenda.
The proposed acquisition builds on the companies’ global distribution and collaboration agreement announced in February 2025.
“Joining Merck will give us the opportunity to combine our expertise in automation with a broader range of quality-control workflow solutions,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. “Our collective capabilities and deep understanding of pharmaceutical manufacturing and quality control will enable us to more fully serve our combined global customer base.”
The transaction is expected to close in December 2026, subject to customary closing conditions.














